The latest research study “Antihyperlipidemic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global antihyperlipidemic drugs market reached a value of US$ 11.31 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 15.81 Billion by 2027, exhibiting a CAGR of 5.20% during 2022-2027.
Request a Free PDF Sample for more detailed market insights: https://www.imarcgroup.com/antihyperlipidemic-drugs-market/requestsample
Antihyperlipidemic drugs are medications used to lower serum levels of cholesterol and lipids (fats) in the blood. Some of the commonly available antihyperlipidemic drugs include bile acid sequestrants, fabric acid derivatives, cholesterol absorption inhibitors, antihyperlipidemic agents, PCSK9 inhibitors, and statins. They are prescribed along with different medications to manage lipid levels in the blood of patients, which can cause various diseases, such as hypertension, diabetes, obesity, and hyperlipidemia. In addition, these drugs help to increase the high-density lipoprotein (HDL) cholesterol in the body to prevent coronary heart conditions.
COVID-19Impact on Market: As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviors of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Antihyperlipidemic Drugs Market Trends and Drivers:
The market is primarily driven by the rising prevalence of hyperlipidemia among individuals due to sedentary lifestyles, consumption of fast foods, and nicotine addiction. In addition, the increasing geriatric population that is more susceptible to developing cardiovascular diseases is contributing to market growth.
Moreover, the increasing incidences of several medical conditions such as diabetes, pregnancy, kidney, and peripheral artery diseases that are likely to result in hyperlipidemia represent another major growth-inducing factor. Besides this, there has been escalated product demand due to the growing prevalence of genetic and acquired lipid and lipoprotein metabolism disorders among the pediatric population to reduce hospitalization rates and premature deaths.
Furthermore, antihyperlipidemic drugs are widely prescribed for reducing low-density lipoprotein (LDL) cholesterol and increasing high-density lipoprotein (HDL) to minimize the risk of coronary artery disease (CAD) in individuals, which is creating a positive market outlook across the globe.
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/antihyperlipidemic-drugs-market
|Antihyperlipidemic Drugs Market Report Scope|
|Market size value in 2021||US$ 11.31 Billion|
|Market forecast in 2027||US$ 15.81 Billion|
|Growth Rate||CAGR of 5.20% from 2022 to 2027|
|Base year for estimation||2021|
Global Antihyperlipidemic Drugs Market 2022-2027 Analysis and Segmentation:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Antihyperlipidemic Drugs Companies:
Amgen Inc., AstraZeneca plc, Daiichi Sankyo Company Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Sanofi S.A.
The report has segmented the market on the basis of region, drug class, route of administration and distribution channel.
Breakup by Drug Class:
- Bile Acid Sequestrants
- Cholesterol Absorption Inhibitors
- Fibric Acid Derivatives
- PCSK9 Inhibitors
Breakup by Route of Administration:
Market Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Stores
- Online Retailers
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: [email protected]
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800